When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit? [Yahoo! Finance]
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: Yahoo! Finance
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. With the latest financial year loss of US$23m and a trailing-twelve-month loss of US$24m, the US$24m market-cap company amplified its loss by moving further away from its breakeven target. Many investors are wondering about the rate at which Evaxion Biotech will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts' expectations for the company. See our latest analysis for Evaxion Biotech Consensus from 3 of the American Biotechs analysts is that Evaxion Biotech is on the verge of breakeven. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$26m in 2025. Therefore, the company is expected to breakeven just over a year from today. In order to meet this breakeven date, we calculated the rate at which the company must gro
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]Yahoo! Finance
- Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01GlobeNewswire
- Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Evaxion Biotech A/S (NASDAQ: EVAX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.MarketBeat
EVAX
Sec Filings
- 4/25/24 - Form 6-K
- 4/17/24 - Form 6-K
- 4/2/24 - Form 6-K
- EVAX's page on the SEC website